MA27581A1 - Vaccin a pseudo-particules virales de la proteine l1 des papillomavirus 16 et 18 - Google Patents
Vaccin a pseudo-particules virales de la proteine l1 des papillomavirus 16 et 18Info
- Publication number
- MA27581A1 MA27581A1 MA28398A MA28398A MA27581A1 MA 27581 A1 MA27581 A1 MA 27581A1 MA 28398 A MA28398 A MA 28398A MA 28398 A MA28398 A MA 28398A MA 27581 A1 MA27581 A1 MA 27581A1
- Authority
- MA
- Morocco
- Prior art keywords
- papillomavirus
- particle vaccine
- papillomavirus protein
- viral pseudo
- pseudo
- Prior art date
Links
- 241001631646 Papillomaviridae Species 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43503502P | 2002-12-20 | 2002-12-20 | |
| US49665303P | 2003-08-20 | 2003-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27581A1 true MA27581A1 (fr) | 2005-10-03 |
Family
ID=32685362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28398A MA27581A1 (fr) | 2002-12-20 | 2005-07-18 | Vaccin a pseudo-particules virales de la proteine l1 des papillomavirus 16 et 18 |
Country Status (28)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000087I1 (de) | 1998-10-16 | 2008-03-27 | Glaxosmithkline Biolog Sa | Adjuvanzsysteme und impfstoffe |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| US7858098B2 (en) | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| US7758866B2 (en) * | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| CA2566620C (en) * | 2004-06-16 | 2014-03-11 | Glaxosmithkline Biologicals S.A. | Vaccine against hpv16 and hpv18 and at least another hpv type slected from hpv 31, 45 or 52 |
| US7691579B2 (en) | 2005-04-15 | 2010-04-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| US20090181052A1 (en) * | 2005-04-26 | 2009-07-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| EP1879614A2 (en) * | 2005-04-26 | 2008-01-23 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| US9364529B2 (en) | 2007-04-29 | 2016-06-14 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of human papillomavirus type 18 |
| CN101293918B (zh) | 2007-04-29 | 2013-03-27 | 北京万泰生物药业股份有限公司 | 截短的人乳头瘤病毒16型l1蛋白 |
| DK2403507T3 (en) * | 2009-03-05 | 2018-06-06 | Jenny Colleen Mccloskey | TREATMENT OF INFECTION |
| MX2011013566A (es) * | 2009-06-19 | 2012-06-28 | Eyegene Inc | Vacunas para cancer cervical. |
| EP3100049B1 (en) | 2014-01-31 | 2019-11-06 | Ulisse Biomed S.R.L. | Biosensors for the detection of infection and associated maladies |
| CA2965498A1 (en) | 2014-10-24 | 2016-04-28 | Hpvvax, Llc. | Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions |
| US10799574B2 (en) | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
| CN107614009A (zh) * | 2015-06-02 | 2018-01-19 | 泰尔茂株式会社 | 含有铝的佐剂组合物及包含其的疫苗组合物 |
| JP7581048B2 (ja) | 2018-03-06 | 2024-11-12 | プレシゲン，インコーポレイテッド | ヒトパピローマウイルスワクチンおよびその使用 |
| AU2019231652B2 (en) | 2018-03-06 | 2025-05-22 | Precigen, Inc. | Hepatitis B vaccines and uses of the same |
| BR112020024699A2 (pt) * | 2018-06-04 | 2021-03-09 | Xiamen University | Mutante da proteína l1 do papilomavírus humano tipo 18 |
| EP3891123A4 (en) | 2018-12-03 | 2022-12-14 | Board of Regents, The University of Texas System | ANALOGS OF OLIGO-BENZAMIDE AND THEIR USE IN THE TREATMENT OF CANCER |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4332596A1 (de) * | 1993-09-24 | 1995-03-30 | Martin Josef Dr Sapp | Monoklonale Antikörper |
| DE122007000015I2 (de) | 1997-09-05 | 2008-01-24 | Medimmune Inc | Methode zur in Vitro auseinander- und wiederzusammensetzung von Papillomavirus virusähnlichen Teilchen (vlps) |
| PT1150712E (pt) * | 1999-02-05 | 2008-12-22 | Merck & Co Inc | Formulações para a vacina do vírus do papiloma humano |
| US6245568B1 (en) | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
| KR20080075560A (ko) * | 2000-06-26 | 2008-08-18 | 엔벤타 바이오파마슈티컬스 코포레이션 | 인간 파필로마 바이러스 치료법 |
-
2003
- 2003-12-18 DK DK03789346.8T patent/DK1572233T3/da active
- 2003-12-18 JP JP2005502554A patent/JP5475939B2/ja not_active Expired - Lifetime
- 2003-12-18 KR KR1020127026719A patent/KR20120118087A/ko not_active Withdrawn
- 2003-12-18 BR BR0317544-8A patent/BR0317544A/pt not_active Application Discontinuation
- 2003-12-18 AT AT03789346T patent/ATE503492T1/de active
- 2003-12-18 AR ARP030104709A patent/AR042530A1/es unknown
- 2003-12-18 MY MYPI20034868A patent/MY144492A/en unknown
- 2003-12-18 MX MXPA05006764A patent/MXPA05006764A/es active IP Right Grant
- 2003-12-18 AU AU2003293942A patent/AU2003293942B2/en not_active Expired
- 2003-12-18 NZ NZ540811A patent/NZ540811A/en not_active IP Right Cessation
- 2003-12-18 PL PL377710A patent/PL215257B1/pl unknown
- 2003-12-18 KR KR1020127027784A patent/KR101361769B1/ko not_active Expired - Lifetime
- 2003-12-18 OA OA1200500189A patent/OA13147A/en unknown
- 2003-12-18 WO PCT/EP2003/014562 patent/WO2004056389A1/en active Application Filing
- 2003-12-18 US US10/540,099 patent/US20060251676A1/en not_active Abandoned
- 2003-12-18 DE DE60336581T patent/DE60336581D1/de not_active Expired - Lifetime
- 2003-12-18 TW TW092135963A patent/TWI349557B/zh not_active IP Right Cessation
- 2003-12-18 CA CA2510457A patent/CA2510457C/en not_active Expired - Lifetime
- 2003-12-18 EP EP03789346A patent/EP1572233B1/en not_active Expired - Lifetime
- 2003-12-18 AP AP2005003347A patent/AP2005003347A0/xx unknown
- 2003-12-18 PT PT03789346T patent/PT1572233E/pt unknown
- 2003-12-18 KR KR1020057011497A patent/KR20050086924A/ko not_active Ceased
- 2003-12-18 EA EA200500834A patent/EA009179B1/ru not_active IP Right Cessation
- 2003-12-18 EA EA200701633A patent/EA200701633A1/ru unknown
-
2005
- 2005-04-26 US US11/114,301 patent/US20050287161A1/en not_active Abandoned
- 2005-06-09 IL IL169085A patent/IL169085A/en active IP Right Grant
- 2005-06-09 IS IS7885A patent/IS2811B/is unknown
- 2005-06-13 NO NO20052846A patent/NO20052846L/no not_active Application Discontinuation
- 2005-06-20 EC EC2005005869A patent/ECSP055869A/es unknown
- 2005-07-18 MA MA28398A patent/MA27581A1/fr unknown
-
2011
- 2011-06-08 CY CY20111100549T patent/CY1111552T1/el unknown
-
2015
- 2015-12-09 BE BE2015C068C patent/BE2015C068I2/fr unknown
- 2015-12-09 BE BE2015C067C patent/BE2015C067I2/fr unknown
- 2015-12-09 BE BE2015C069C patent/BE2015C069I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27581A1 (fr) | Vaccin a pseudo-particules virales de la proteine l1 des papillomavirus 16 et 18 | |
| UA85536C2 (en) | Viral antigens | |
| ATE508735T1 (de) | Pulmonale verabreichung von aminoglykosiden | |
| BRPI0307702B8 (pt) | formulações de solução contendo anticorpo | |
| MXPA05009580A (es) | Vacuna contra el virus de la influenza. | |
| WO2004060308A3 (en) | Thiosemicarbazones as anti-virals and immunopotentiators | |
| CY1111212T1 (el) | Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ | |
| CR20120356A (es) | Nuevos compuestos heterocíclicos activos como inhibidores de beta-lactamasas | |
| EA200500584A1 (ru) | Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c | |
| DK1556021T3 (da) | Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger | |
| BR0110998A (pt) | Derivados de fenilglicina | |
| DK1292328T3 (da) | Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse | |
| NO20050917L (no) | Thiomolybdatanaloger og anvendelser derav | |
| FR2827605B1 (fr) | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin | |
| EA200601219A1 (ru) | Новые конденсированные пирролокарбазолы | |
| DK1425404T3 (da) | Vaccinia-MVA-E3L-mutanter og anvendelse deraf | |
| WO2004085682A3 (de) | Caspase inhibitoren, insbesondere von caspase-3, zur behandlung von influenza | |
| NO20050090L (no) | Fremgangsmate for fremstilling av et virus-inaktivert trombinpreparat | |
| FR2792206B1 (fr) | Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1 | |
| DK1476467T3 (da) | IgG3-immunglobulin som beskyttelsesmarkör mod virusinfektionssygdomme og anvendelser deraf | |
| UA107177C2 (uk) | Імуногенна композиція цвс2 та спосіб приготування такої композиції | |
| MX2007002659A (es) | Composicion vacunal contra el virus de la hepatitis c. | |
| GB0221169D0 (en) | Crystal | |
| DK1778271T3 (da) | Peptid til behandling af herpesvirusinfektioner | |
| SE0004892D0 (sv) | Group 2 allergen specific IgE-Fabs and use thereof |